SNX-2112, also known as PF-04928473, is primarily investigated for its potential in cancer therapy. It functions as a heat shock protein 90 (HSP90) inhibitor, targeting the chaperone protein that plays a crucial role in stabilizing and activating numerous oncogenic client proteins. By inhibiting HSP90, SNX-2112 disrupts the stability and function of these client proteins, leading to the degradation of cancer-promoting molecules and ultimately inducing apoptosis in cancer cells. This mechanism makes it a promising candidate for treating various cancers, including those resistant to conventional therapies. Research has shown its efficacy in preclinical models of multiple myeloma, breast cancer, and other malignancies, highlighting its potential as a targeted therapeutic agent. Additionally, its ability to selectively target cancer cells while sparing normal cells reduces the risk of severe side effects, making it an attractive option for further clinical development.